Should we use milrinone or dobutamine in patients in cardiogenic shock? NEJM published data providing us with the answer.

In this episode, we explore the topic of cardiogenic shock and the use of two common medications, milrinone and dobutamine, in treating it. We examine the mechanisms of action, potential side effects, and clinical outcomes associated with each drug to determine which may be the better option for patients. Join us as we delve into this complex and important topic in critical care medicine.

Show Notes: https://eddyjoemd.com/milrinone-dobutamine/

TrueLearn Link: https://truelearn.referralrock.com/l/EDDYJOEMD25/

Citation: Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. N Engl J Med. 2021 Aug 5;385(6):516-525. doi: 10.1056/NEJMoa2026845. PMID: 34347952.